Autopsy report · NCT04082936

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“Strategic Pipeline Prioritization: Clinical development of imvotamab in autoimmune diseases prioritized.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 4 years 5 months before it stopped.
97 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1, Phase 2
Sponsor: IGM Biosciences, Inc.
Sponsor type: Industry
Conditions: Non-Hodgkin Lymphoma; Follicular Lymphoma; DLBCL; Mantle Cell Lymphoma; Marginal Zone Lymphoma
Interventions: imvotamab
Participants: 97
Sites: 26
Countries: Australia, Czechia, France, Italy, South Korea, Spain, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.